Cancer Fear: Facilitator and Deterrent to Participation in Colorectal Cancer Screening

Charlotte Vrinten, Jo Waller, Christian von Wagner, and Jane Wardle

Abstract

Background: Cancer fear has been associated with higher and lower screening uptake across different studies, possibly because different aspects of cancer fear have different effects on intentions versus behavior. The present study examined associations of three aspects of cancer fear with intention and uptake of endoscopic screening for colorectal cancer.

Methods: A subsample of UK Flexible Sigmoidoscopy (FS) Trial participants received a baseline questionnaire that included three cancer fear items from a standard measure asking if: (i) cancer was feared more than other diseases, (ii) cancer worry was experienced frequently, and (iii) thoughts about cancer caused discomfort. Screening intention was assessed by asking participants whether, if invited, they would accept an invitation for FS screening. Positive responders were randomized to be invited or not in a 1:2 ratio. The behavioral outcome was clinic-recorded uptake. Control variables were age, gender, ethnicity, education, and marital status.

Results: The questionnaire return rate was 60% (7,971/13,351). The majority (82%) intended to attend screening; 1,920 were randomized to receive an invitation, and 71% attended. Fearing cancer more than other diseases (OR = 2.32, \( P < 0.01 \)) and worrying a lot about cancer (OR = 2.34, \( P < 0.01 \)) increased intentions to attend screening, but not uptake. Finding thoughts about cancer uncomfortable did not influence intention, but predicted lower uptake (OR = 0.72, \( P < 0.01 \)).

Conclusions: Different aspects of cancer fear have different effects on the decision and action processes leading to screening participation.

Impact: Knowledge of the different behavioral effects of cancer fear may aid the design of effective public health messages. Cancer Epidemiol Biomarkers Prev; 24(2); 1–6. ©2015 AACR.

Introduction

Cancer fear has been implicated both as a facilitator and a deterrent to screening uptake. A meta-analysis of 12 prospective studies in breast cancer found a linear relationship between cancer fear and screening uptake (1). However, two studies examining colorectal screening uptake found no association with fear (2, 3), whereas other studies of breast screening (4–7), and of prostate (4) and ovarian cancer screening (8), found a curvilinear relationship, with both low and high fear associated with lower uptake.

One possible explanation for the varying results could be that the studies used different measures of cancer fear, and the effects of screening participation could vary depending on the aspect of fear examined (9, 10). Fear is best understood as a multidimensional construct, with loosely coupled cognitive, biologic, affective, and behavioral components (11). Fear of cancer has been operationalized in many ways, for example, “worry about cancer,” “cancer-related distress,” “intrusive and avoidant thoughts about cancer,” and “effects of cancer-related thoughts on mood and daily activities” (9). Cancer worry could promote screening uptake as a means of seeking reassurance, at least among individuals who perceive their risk as low, whereas avoidant or fatalistic views may be a deterrent to screening (6, 9, 10). The observed effect in any individual study could depend on the specific fear indicator used.

Several studies have used multiple item scales covering several different aspects of cancer fear, but have usually combined them into a single fear score to predict behavior, making it difficult to assess the independent effect of individual fear components (5, 12). However, in two studies, one of breast and one of prostate cancer, cancer worry was associated with a stronger intention to obtain screening and more frequent screening, whereas fear about screening itself and its results was associated with lower intention and less frequent screening (13, 14). Wong and colleagues (15) found similar relationships for colorectal cancer in a sample of older adults in Singapore: worry was associated with higher uptake, whereas fear of cancer being found during screening was associated with lower uptake. A similar pattern emerged in a sample of low-income Hispanic Americans (16): levels of cancer worry were higher among those who had received colonoscopy screening, whereas levels of fatalism were (nonsignificantly) higher among those who had not been screened.

No study has explicitly tested the relative contributions of cognitive, biologic, and affective components of fear on screening participation. We therefore used prospective data from the UK Flexible Sigmoidoscopy (FS) Trial to examine the association between these three aspects of cancer fear and two indices of participation: intention and uptake of screening for colorectal cancer.
Materials and Methods

Design
Data for this secondary analysis come from a subsample of participants (n = 13,351) in the UK FS Trial who had been sent an extended baseline questionnaire before their screening invitation. Data were collected between 1996 and 1999. The UK FS Trial is a multicenter randomized controlled trial assessing the effect of once-only FS screening in adults ages 55 to 64 years on colorectal cancer incidence and mortality (17, 18). It used a two-step recruitment process to increase statistical power in intention-to-treat analyses. Potential participants (n = 375,744) were all adults ages 55 to 64 years in 506 participating General Practices (GP) across the UK. After exclusions by GPs, 368,142 participants were sent information about the Trial, together with a baseline questionnaire asking about intention to attend FS screening ("If you were invited to have the bowel cancer screening test, would you take up the offer: yes definitely, yes probably, probably not, definitely not"). Those who answered "yes probably" or "yes definitely" were randomized in a 1:2 ratio to receive an invitation for FS screening or care-as-usual, as per the Trial protocol (17). Ethics approval was obtained from the local research ethics committee for all participating centers.

Participants
Participants (n = 13,351) in a subsample of Practices were randomly selected to take part in a psychologic substudy of the main FS trial. These participants received a longer version of the baseline questionnaire that included items on cancer fear, demographics, health, and psychosocial measures. Our sample for analyses of associations between cancer fear and screening intention consisted of this subsample (Sample 1). Among those who responded that they would "probably" or "definitely" take up the offer of screening, and were therefore entered into the randomization schedule, 1,995 were randomized to receive a screening invitation. This constituted our sample for analyses of screening uptake (Sample 2). All participants were naive to colorectal cancer screening, which was not part of the UK National Cancer Screening Programme at the time of the study.

Screening intention and uptake
Screening intention was based on the questionnaire responses described above (Sample 1). For the analyses of associations between fear and screening intention, responses to the screening intention question were dichotomized (yes definitely/yes probably vs. probably not/definitely not). Screening uptake was recorded in the clinic (attended vs. did not attend) for all participants randomized to be sent a screening invitation (Sample 2). Clinic records of screening attendance for those who were invited were 100% complete.

Cancer fear
Three aspects of cancer fear were assessed in the baseline questionnaire, each with a single-item statement. One item reflected a more cognitive evaluation of cancer fear ("Of all the diseases there are, I am most afraid of cancer"), one reflected a more affective response to cancer ("I worry a lot about cancer"), and one was more psychobiologic ("It makes me uncomfortable to think about cancer"). Responses were on 5 point scales: "strongly disagree," "disagree," "not sure," "agree," and "strongly agree." We combined the "agree" and "strongly agree" categories for the multi-variate logistic regression analyses examining the associations of fear with screening interest and uptake, because we were interested in the effect of the presence of cancer fear. We combined the "strongly disagree" and "disagree" categories to create a robust reference group of people without cancer fear, because numbers for the "strongly disagree" category were small. "Not sure" was treated as the mid-point because it was physically placed between "agree" and "disagree" on the response scale on the questionnaire, but we did sensitivity analyses excluding respondents with "not sure" responses.

Sociodemographic control variables
Demographic data included age, gender, ethnicity, educational qualifications, and marital status. Age and gender were taken from GP records. Ethnicity was assessed with the question "which of these best describes your ethnic background," with response categories "White," "Black," "Asian," "Other," "Do not wish to answer." Numbers for "Black" (n = 99), "Asian" (n = 183), and "Other" (n = 43) were small, and therefore combined in a "non-White" category. "Do not wish to answer" was coded as missing. A single item was used to record education: "do you have any educational qualifications?" (e.g., School Certificate, GCE O'Levels, etc.), with "yes" or "no" response options. In this cohort, born between 1932 and 1943, continuation in education would have depended on passing these examinations taken at age 16. Education is a good index of socioeconomic status in older adults (19). Marital status was assessed with "what is your marital status," with response categories dichotomized into "married or cohabiting" and "not married or cohabiting." For all demographics, missing data were coded as a separate category.

Statistical analysis
Percentages of respondents intending to attend (Sample 1), and attending (Sample 2), were analyzed in relation to each fear indicator. Multivariate logistic regression analyses for each cancer fear indicator individually were used to examine associations with screening intention (Sample 1) and uptake (Sample 2), using the dichotomized variables for screening intention and uptake, and adjusting for differences in sociodemographic characteristics. "Not sure" was used as mid-point for the cancer fear indicators in these analyses, but a sensitivity analysis was performed in which this category was coded as missing. We also conducted a sensitivity analysis with all categories for the fear items. Bonferroni corrections were applied to control for the family-wise error rate due to multiple comparisons, and a P value of 0.01 was used to indicate statistical significance. SPSS version 22.0 was used for all analyses.

Results
Return rate of the extended baseline questionnaire was 60% (7,971/13,351). Almost all respondents (98%; n = 7,780) had a valid response on the screening intention question, and 91% (n = 7,327) had complete data on all three cancer fear indicators; this constituted Sample 1. Of this group, 82% intended to take up the offer of screening if invited, with 53% saying they would probably attend and 29% that they would definitely attend. A flow diagram of the inclusion process is presented in Fig. 1. Among those who said they would either probably or definitely attend (6,299/7,780), 1,995 were randomized to receive a screening invitation as per the Trial protocol. The majority (96%; 1,920/1,995) had
Cancer fear and screening intention

The first set of analyses examined associations between each fear item and intention to attend in Sample 1 (n = 7,327; see Table 1). There were slightly more women (54%) than men (46%) in this sample. More than half (60%) did not have any educational qualifications, the majority (93%) were from a White ethnic background, and 73% were married or cohabiting.

Overall, 59% of respondents agreed or strongly agreed that they were more afraid of cancer than other diseases; 53% agreed or strongly agreed that they felt uncomfortable thinking about cancer, and 25% agreed or strongly agreed that they worried a lot about cancer. As previously reported in this sample (20), Spearman correlations between the cancer fear items (before the extreme categories were grouped together) were modest: between 0.36 and 0.42 (Table 2). This suggests that there is some commonality between these indicators of cancer fear but that they also tap into different aspects (20).

More respondents who reported having cancer as their greatest health fear said they intended to attend screening: 86% versus 79% of those who were not sure, and 74% of those who disagreed (Table 3). The same relationship was observed for cancer worry: 89% of those who worried about cancer a lot intended to attend, compared with 83% of those who were unsure, and 79% of those who did not worry about cancer. However, the pattern was different for feeling uncomfortable thinking about cancer: 80% intended to attend among those who agreed with this item, versus 75% of those who were unsure, and 72% of those who disagreed (Table 3). The same relationship was observed for worry: 86% of those who were very afraid of cancer intended to attend screening, versus 83% of those who were unsure, and 79% of those who did not worry about cancer. However, the pattern was different for feeling uncomfortable thinking about cancer: 80% intended to attend among those who agreed with this item, versus 75% of those who were unsure, and 72% of those who disagreed (Table 3). The same relationship was observed for worry: 86% of those who were very afraid of cancer intended to attend screening, versus 83% of those who were unsure, and 79% of those who did not worry about cancer.

Adjusted logistic regression analyses controlling for age, gender, education, ethnicity, and marital status are shown in Table 3. Having cancer as greatest health fear and worrying about cancer a lot were associated with greater screening intention. Discomfort when thinking about cancer did not affect intention to attend screening. Sensitivity analyses in which the “not sure” category was coded as missing showed the same pattern: having cancer as the greatest health fear and worrying about cancer a lot were associated with an increased likelihood to intend to attend screening. Discomfort did not affect screening intention (results not shown). We also repeated the analysis with all the fear categories. The results showed a similar pattern in terms of associations with screening intentions (results not shown); we chose to report the results for the largest sample size.

Cancer fear and screening uptake

The second set of analyses examined uptake among the group who had said they intended to attend screening and were randomized to be invited (Sample 2). There were slightly more women (52%) than men (48%) in this sample, the majority (58%) did not have any educational qualifications, most (93%) were of White ethnic background, and most (75%) were married or cohabiting (Table 1).

Spearman correlations between the cancer fear indicators for Samples 1 and 2

<table>
<thead>
<tr>
<th></th>
<th>Sample 1 N (%)</th>
<th>Sample 2 N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample 1</td>
<td>Sample 2</td>
<td></td>
</tr>
<tr>
<td>Sample 1</td>
<td>Sample 2</td>
<td></td>
</tr>
<tr>
<td>Greatest health fear</td>
<td>0.42</td>
<td>0.38</td>
</tr>
<tr>
<td>Worry</td>
<td>0.42</td>
<td>0.36</td>
</tr>
<tr>
<td>Discomfort</td>
<td>0.42</td>
<td>0.36</td>
</tr>
</tbody>
</table>

NOTE: All correlations are significant at \( P < 0.001 \).
In this group, more than half (64%) agreed or strongly agreed that they were more afraid of cancer than other diseases, 52% felt uncomfortable thinking about cancer, and 28% worried a lot about cancer. The higher percentages of having cancer as the greatest health fear and cancer worry than in Sample 1, and the slightly lower percentage of discomfort thinking about cancer, reflect the associations between these variables and screening intention.

In terms of percentages attending, those who reported higher fear on any of the three fear indicators were slightly less likely to actually take part in screening (Table 4). Of those who reported that cancer was their greatest health fear, 70% attended FS screening, compared with 72% for whom it was not. For cancer worry, 65% of those who reported worrying a lot attended screening, versus 72% of those who did not worry about cancer. For discomfort thinking about cancer, 68% of those who felt uncomfortable attended screening, versus 77% of those who did not feel uncomfortable.

In adjusted logistic regression analyses controlling for age, gender, education, ethnicity, and marital status (Table 4), only discomfort thinking about cancer had a significant deterrent effect on screening uptake in those who had previously indicated that they intended to attend [OR 0.72 (0.56–0.91), P < 0.01]. We conducted a sensitivity analysis in which the "not sure" category was coded as missing; this showed the same pattern of results (results not shown). A second sensitivity analysis using all categories for the three cancer fear variables also showed a similar relationship between cancer fear and screening uptake. We therefore reported the analysis with the largest sample size.

**Discussion**

This is the largest study to date to have recorded information on cancer fear before a screening invitation was offered, to have clinic records of uptake as well as reported intention, and to explicitly compare different aspects of cancer fear. In terms of screening intention, we found evidence that the cognitive/affective aspects of cancer fear (cancer as greatest health fear, worry about cancer) were significant facilitators of screening intention, whereas the more psychobiologic aspect (discomfort thinking about cancer) was not significantly related to screening intention. Once those who were interested in screening were invited, the cognitive/affective aspects of cancer fear did not have any residual effect on actual behavior (screening uptake). In contrast, discomfort thinking about cancer, which had not affected intention, was a deterrent to taking part in cancer screening in this sample who had already indicated an intention to attend.

These findings lend support to the idea that different aspects of cancer fear may have different behavioral effects, but also that they may exert their effects at different stages in the decisional process. In line with results from earlier studies (13, 15, 16), we found that cancer worry facilitated screening through enhancing intention to attend—perhaps motivated by a desire for reassurance, whereas a more visceral negative response to thinking about a cancer acted as a deterrent at the action stage. The distinction between influences on intention and action is an important emerging area of work in helping to understand the “intention–behavior gap” (21). Although the behavioral effects of these three aspects of cancer fear may be different, a previous study has shown that their sociodemographic correlates are largely similar, with women, and those without educational qualifications and from ethnic minority backgrounds most affected (20). In addition to the different ways in which cancer fear is experienced (i.e., as worry, distress, intrusive thoughts, etc.), some authors have noted that there may also be individual differences in the object of cancer fear and the associated behavioral effects (e.g., fear of a cancer diagnosis, fear of dying from cancer, etc.; see for example, ref. 10), although these distinctions were beyond the scope of the present study.

Some cross-sectional studies have assessed the effects of cancer fear by using past screening uptake as the outcome (4, 5, 8). The disadvantage of this approach is that past screening results may influence subsequent cancer fear, a problem known as “reverse causality” (9). The present study avoids the problem of reverse causality because cancer fear was measured in a screening-naïve sample before any screening invitation. It thus contributes to our understanding of the influence of different aspects of cancer fear on intentions and behavior, and also stresses the importance of measuring behavior (and not only intentions) when assessing health behaviors.

One limitation of the present study was that data about cancer fear and screening interest were collected at the same time, meaning that the possibility of reverse causality remains an issue.

### Table 3. Percentages, adjusted ORs, and 95% confidence intervals for intending to attend FS screening (“yes probably”/“yes definitely”), by each cancer fear indicator (Sample 1; n = 7,327)

<table>
<thead>
<tr>
<th></th>
<th>Intending to attend</th>
<th>Adjusted OR* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Greatest health fear</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Strongly) disagree</td>
<td>1,207 (74.4)</td>
<td>Ref.</td>
</tr>
<tr>
<td>Not sure</td>
<td>1,108 (76.6)</td>
<td>1.30 (1.09–1.54)</td>
</tr>
<tr>
<td>(Strongly) agree</td>
<td>3,681 (85.7)</td>
<td>2.32 (2.01–2.69)</td>
</tr>
<tr>
<td>Worry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Strongly) disagree</td>
<td>3,481 (78.8)</td>
<td>Ref.</td>
</tr>
<tr>
<td>Not sure</td>
<td>870 (83.0)</td>
<td>1.38 (1.15–1.65)</td>
</tr>
<tr>
<td>(Strongly) agree</td>
<td>1,645 (88.5)</td>
<td>2.34 (1.99–2.75)</td>
</tr>
<tr>
<td>Discomfort</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Strongly) disagree</td>
<td>1,834 (83.1)</td>
<td>Ref.</td>
</tr>
<tr>
<td>Not sure</td>
<td>1,076 (85.1)</td>
<td>1.22 (1.00–1.47)</td>
</tr>
<tr>
<td>(Strongly) agree</td>
<td>3,086 (80.1)</td>
<td>0.88 (0.76–1.01)</td>
</tr>
</tbody>
</table>

*Adjusted for age, gender, education, ethnicity, and marital status.

### Table 4. Percentages, adjusted ORs, and 95% confidence intervals for intending FS screening, by each cancer fear indicator (Sample 2; n = 1,920)

<table>
<thead>
<tr>
<th></th>
<th>Attended N (%)</th>
<th>Adjusted OR* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Greatest health fear</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Strongly) disagree</td>
<td>267 (72.2)</td>
<td>Ref.</td>
</tr>
<tr>
<td>Not sure</td>
<td>238 (73.0)</td>
<td>1.10 (0.78–1.55)</td>
</tr>
<tr>
<td>(Strongly) agree</td>
<td>854 (69.8)</td>
<td>1.06 (0.81–1.38)</td>
</tr>
<tr>
<td>Worry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Strongly) disagree</td>
<td>807 (72.4)</td>
<td>Ref.</td>
</tr>
<tr>
<td>Not sure</td>
<td>202 (74.8)</td>
<td>1.19 (0.87–1.63)</td>
</tr>
<tr>
<td>(Strongly) agree</td>
<td>350 (65.4)</td>
<td>0.83 (0.66–1.05)</td>
</tr>
<tr>
<td>Discomfort</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Strongly) disagree</td>
<td>456 (77.2)</td>
<td>Ref.</td>
</tr>
<tr>
<td>Not sure</td>
<td>230 (67.6)</td>
<td>0.68 (0.50–0.92)</td>
</tr>
<tr>
<td>(Strongly) agree</td>
<td>673 (68.0)</td>
<td>0.72 (0.56–0.91)</td>
</tr>
</tbody>
</table>

*Adjusted for age, gender, education, ethnicity, and marital status.

bP = 0.012.

cP < 0.01.
for the associations between cancer fear and screening interest. This causal direction can only be established through further longitudinal or interventional studies.

Our study also had other limitations. Response rate to the baseline questionnaire (60%) was good for a community-based survey, but still meant we had no information on intentions on the 40% of nonresponders. Participants could see that the questionnaire was about cancer and those with higher levels of cancer fear may have been less likely to return it. If cancer fear is a cause of nonresponse, then the high proportions of those endorsing the fear statements would in fact be an underrepresentation of the prevalence of cancer fear in older adults. The cancer fear measures that were used were not specific to colorectal cancer. Although many previous studies have used specific colorectal cancer fear measures to determine the effect on intentions and uptake of screening (2, 22), we had chosen more general measures because they may better reflect cancer fear as experienced by the general population (i.e., as a nonspecific “fear of cancer,” rather than a specific “fear of colorectal cancer”), and because they allow for future comparisons of the behavioral effects of these aspects of cancer fear across different types of cancer screening. In addition, we used single-item measures. However, the moderate correlation between the items, the different endorsement rates, and the differential relationships with screening interest and uptake support the idea that the items represent different aspects of cancer fear that may need to be distinguished if we seek to understand the behavioral effects of cancer fear (9, 10).

The trial design imposed limitations because it specified only inviting respondents who expressed some interest in attending. We therefore do not know how many “nonintenders” might actually have attended if they had received an invitation, nor whether the associations between cancer fear and screening uptake would have been similar in this group. Future studies that invite all potential participants to take part in screening—regardless of screening intentions—would reduce any bias that may have been introduced by the sampling method used in the current study. Finally, in the questionnaire, “not sure” was presented as the midpoint of the response scale for the cancer fear indicators, between disagree and agree. This category was also used as the midpoint for the analyses. However, some participants may have interpreted this response option as “don’t know,” rather than as midpoint of an agreement scale, as demonstrated by others (23). We therefore carried out sensitivity analyses omitting respondents who endorsed “not sure,” which did not change the broad pattern of results.

Conclusions

The results of this study confirm that cancer fear can be a facilitator or a deterrent, depending on the specific aspect of fear. Having cancer as the greatest health fear or worrying a lot about cancer facilitated intentions to attend, whereas finding thoughts of cancer uncomfortable did not affect intention but was a deterrent to actual uptake. Learning more about the make-up of cancer fear, and having more nuanced analyses of the behavioral effects, might help in the design of effective public health messages.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Disclaimer

Cancer Research UK was not involved in the design of this study; the collection, analysis, or interpretation of the results; in the writing of the article; or in the decision to submit for publication.

Authors’ Contributions

Conception and design: C. Vrinten, J. Wardle
Development of methodology: J. Wardle
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J. Wardle
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C. Vrinten, J. Waller, C. von Wagner, J. Wardle
Writing, review, and/or revision of the manuscript: C. Vrinten, J. Waller, C. von Wagner, J. Wardle
Study supervision: J. Wardle

Acknowledgments

The authors thank Professor Wendy Atkin (Principal Investigator for the UK Flexible Sigmoidoscopy Trial) for letting them use data from the UK FS Trial for the current study.

Grant Support

This study was supported by a programme grant from Cancer Research UK awarded to Professor Jane Wardle (C1418/A14134). All authors are funded by this grant. The UK FS Trial was funded by the Medical Research Council, National Health Service R&D, Cancer Research UK, and KeyMed. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 21, 2014; revised November 18, 2014; accepted November 18, 2014; published OnlineFirst January 29, 2015.

References

Cancer Fear: Facilitator and Deterrent to Participation in Colorectal Cancer Screening


Cancer Epidemiol Biomarkers Prev  Published OnlineFirst January 29, 2015.

Updated version  Access the most recent version of this article at:
doi:10.1158/1055-9965.EPI-14-0967

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.